Related references
Note: Only part of the references are listed.Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations A Nonrandomized, Noncontrolled Trial
Stephen Mullin et al.
JAMA NEUROLOGY (2020)
Nurr1: A vital participant in the TLR4-NF-κB signal pathway stimulated by α-synuclein in BV-2 cells
Qian-Hang Shao et al.
NEUROPHARMACOLOGY (2019)
The glutathione cycle shapes synaptic glutamate activity
Thomas W. Sedlak et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Increased Immune Activation by Pathologic α-Synuclein in Parkinson's Disease
Veselin Grozdanov et al.
ANNALS OF NEUROLOGY (2019)
Intestinal infection triggers Parkinson's disease-like symptoms in Pink1-/- mice
Diana Matheoud et al.
NATURE (2019)
Miro1 Marks Parkinson's Disease Subset and Miro1 Reducer Rescues Neuron Loss in Parkinson's Models
Chung-Han Hsieh et al.
CELL METABOLISM (2019)
Current Progress of Mitochondrial Quality Control Pathways Underlying the Pathogenesis of Parkinson's Disease
Xue Jiang et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2019)
A modulator of wild-type glucocerebrosidase improves pathogenic phenotypes in dopaminergic neuronal models of Parkinson's disease
Lena F. Burbulla et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Simvastatin as a neuroprotective treatment for Parkinson's disease (PD STAT): protocol for a double-blind, randomised, placebo-controlled futility study
Camille B. Carroll et al.
BMJ OPEN (2019)
Blockade of the K-ATP channel Kir6.2 by memantine represents a novel mechanism relevant to Alzheimer's disease therapy
S. Moriguchi et al.
MOLECULAR PSYCHIATRY (2018)
High-dose transdermal nicotine in Parkinson's disease patients: a randomized, open-label, blinded-endpoint evaluation phase 2 study
G. Villafane et al.
EUROPEAN JOURNAL OF NEUROLOGY (2018)
Repeated-Dose Oral N-Acetylcysteine in Parkinson's Disease: Pharmacokinetics and Effect on Brain Glutathione and Oxidative Stress
Lisa D. Coles et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2018)
A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Dopamine D1 Receptor Partial Agonist, PF-06669571, in Subjects with Idiopathic Parkinson's Disease
Rachel Gurrell et al.
CLINICAL DRUG INVESTIGATION (2018)
A novel selective MAO-B inhibitor with neuroprotective and anti-Parkinsonian properties
Hugh H. Chan et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2018)
Peripheral monocyte entry is required for alpha-Synuclein induced inflammation and Neurodegeneration in a model of Parkinson disease
Ashley S. Harms et al.
EXPERIMENTAL NEUROLOGY (2018)
Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease
Seung Pil Yun et al.
NATURE MEDICINE (2018)
Serum caffeine and metabolites are reliable biomarkers of early Parkinson disease
Motoki Fujimaki et al.
NEUROLOGY (2018)
Diabetes mellitus and Parkinson disease
Gennaro Pagano et al.
NEUROLOGY (2018)
Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-a-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease A Randomized Clinical Trial
Joseph Jankovic et al.
JAMA NEUROLOGY (2018)
Simvastatin Inhibits Activation of NADPH Oxidase/p38 MAPK Pathway and Enhances Expression of Antioxidant Protein in Parkinson Disease Models
Huichun Tong et al.
FRONTIERS IN MOLECULAR NEUROSCIENCE (2018)
Levodopa in Parkinson's Disease: Current Status and Future Developments
Nicola Tambasco et al.
CURRENT NEUROPHARMACOLOGY (2018)
Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs
Delphine Charvin et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Reduced glucocerebrosidase activity in monocytes from patients with Parkinson's disease
Farzaneh Atashrazm et al.
SCIENTIFIC REPORTS (2018)
Mitochondrial dysfunction and increased glycolysis in prodromal and early Parkinson's blood cells
Amy M. Smith et al.
MOVEMENT DISORDERS (2018)
First-in-human assessment of PRX002, an anti--synuclein monoclonal antibody, in healthy volunteers
Dale B. Schenk et al.
MOVEMENT DISORDERS (2017)
Alpha-synuclein oligomer-selective antibodies reduce intracellular accumulation and mitochondrial impairment in alpha-synuclein exposed astrocytes
Gabriel Gustafsson et al.
JOURNAL OF NEUROINFLAMMATION (2017)
Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial
Dilan Athauda et al.
LANCET (2017)
Extensive uptake of α-synuclein oligomers in astrocytes results in sustained intracellular deposits and mitochondrial damage
Veronica Lindstrom et al.
MOLECULAR AND CELLULAR NEUROSCIENCE (2017)
NADPH oxidases in Parkinson's disease: a systematic review
Karim Belarbi et al.
MOLECULAR NEURODEGENERATION (2017)
A Randomized Trial of a Low-Dose Rasagiline and Pramipexole Combination (P2B001) in Early Parkinson's Disease
C. Warren Olanow et al.
MOVEMENT DISORDERS (2017)
Neurotoxic reactive astrocytes are induced by activated microglia
Shane A. Liddelow et al.
NATURE (2017)
Exenatide - a drug for diabetes and Parkinson disease?
Joseph Jankovic
NATURE REVIEWS NEUROLOGY (2017)
Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease
Fabrizio Stocchi et al.
NEUROLOGY (2017)
Caffeine as symptomatic treatment for Parkinson disease (Cafe-PD) A randomized trial
Ronald B. Postuma et al.
NEUROLOGY (2017)
Metabotropic glutamate receptors and neurodegenerative diseases
Fabiola M. Ribeiro et al.
PHARMACOLOGICAL RESEARCH (2017)
Nurr1:RXRα heterodimer activation as monotherapy for Parkinson's disease
Athanasios D. Spathis et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Expanding the repertoire of L-DOPA's actions: A comprehensive review of its functional neurochemistry
Philippe De Deurwaerdere et al.
PROGRESS IN NEUROBIOLOGY (2017)
Structural basis of membrane disruption and cellular toxicity by α-synuclein oligomers
Giuliana Fusco et al.
SCIENCE (2017)
Simvastatin as a Potential Disease-Modifying Therapy for Patients with Parkinson's Disease: Rationale for Clinical Trial, and Current Progress
Camille B. Carroll et al.
JOURNAL OF PARKINSONS DISEASE (2017)
Current understanding of the molecular mechanisms in Parkinson's disease: Targets for potential treatments
Panchanan Maiti et al.
TRANSLATIONAL NEURODEGENERATION (2017)
Nicotine slows down oligomerisation of α-synuclein and ameliorates cytotoxicity in a yeast model of Parkinson's disease
Jay Kardani et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2017)
The Benzopyrone Biochanin-A as a reversible, competitive, and selective monoamine oxidase B inhibitor
Najla O. Zarmouh et al.
BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE (2017)
Apocyanin, a Microglial NADPH Oxidase Inhibitor Prevents Dopaminergic Neuronal Degeneration in Lipopolysaccharide-Induced Parkinson's Disease Model
Neha Sharma et al.
MOLECULAR NEUROBIOLOGY (2016)
Ambroxol effects in glucocerebrosidase and -synuclein transgenic mice
Anna Migdalska-Richards et al.
ANNALS OF NEUROLOGY (2016)
Novel Levodopa Formulations for Parkinson's Disease
Maria Eliza Freitas et al.
CNS DRUGS (2016)
Nurr1-Based Therapies for Parkinson's Disease
Jie Dong et al.
CNS NEUROSCIENCE & THERAPEUTICS (2016)
Current Pharmaceutical Treatments and Alternative Therapies of Parkinson's Disease
Jie Dong et al.
CURRENT NEUROPHARMACOLOGY (2016)
The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action
Dilan Athauda et al.
DRUG DISCOVERY TODAY (2016)
Mavoglurant in Parkinson's patients with l-Dopa-induced dyskinesias: Two randomized phase 2 studies
Claudia Trenkwalder et al.
MOVEMENT DISORDERS (2016)
A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease
Francois Tison et al.
MOVEMENT DISORDERS (2016)
A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease
Peter A. LeWitt et al.
MOVEMENT DISORDERS (2016)
Adjunctive preladenant: A placebo-controlled, dose-finding study in Japanese patients with Parkinson's disease
Nobutaka Hattori et al.
PARKINSONISM & RELATED DISORDERS (2016)
Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson's disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs
Sven E. Palhagen et al.
PARKINSONISM & RELATED DISORDERS (2016)
Insulin resistance and Parkinson's disease: A new target for disease modification?
D. Athauda et al.
PROGRESS IN NEUROBIOLOGY (2016)
Selective brain penetrable Nurr1 transactivator for treating Parkinson's disease
Jun Wang et al.
ONCOTARGET (2016)
Evolution of NADPH Oxidase Inhibitors: Selectivity and Mechanisms for Target Engagement
Sebastian Altenhofer et al.
ANTIOXIDANTS & REDOX SIGNALING (2015)
GBA deficiency promotes SNCA/α-synuclein accumulation through autophagic inhibition by inactivated PPP2A
Ting-Ting Du et al.
AUTOPHAGY (2015)
Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations
Roy N. Alcalay et al.
BRAIN (2015)
Post-treatment with an ultra-low dose of NADPH oxidase inhibitor diphenyleneiodonium attenuates disease progression in multiple Parkinson's disease models
Qingshan Wang et al.
BRAIN (2015)
Mitochondria: A Therapeutic Target for Parkinson's Disease?
Yu Luo et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2015)
Gastrointestinal dysfunction in Parkinson's disease
Alfonso Fasano et al.
LANCET NEUROLOGY (2015)
NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators. Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. (vol 14, pg 795, 2015)
Chadwick W. Christine
LANCET NEUROLOGY (2015)
Gastroretentive Carbidopa/Levodopa, DM-1992, for the Treatment of Advanced Parkinson's Disease
Leo Verhagen Metman et al.
MOVEMENT DISORDERS (2015)
The Roles of PINK1, Parkin, and Mitochondrial Fidelity in Parkinson's Disease
Alicia M. Pickrell et al.
NEURON (2015)
Nuclear receptor Nurr1 agonists enhance its dual functions and improve behavioral deficits in an animal model of Parkinson's disease
Chun-Hyung Kim et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Mitochondrial dysfunction and mitophagy in Parkinson's: from familial to sporadic disease
Brent J. Ryan et al.
TRENDS IN BIOCHEMICAL SCIENCES (2015)
Neuroinflammation in Parkinson's disease and its potential as therapeutic target
Qinqin Wang et al.
TRANSLATIONAL NEURODEGENERATION (2015)
Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis
Hui-Fu Wang et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2015)
Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial
Tanya Simuni et al.
LANCET NEUROLOGY (2015)
Environmental Toxins and Parkinson's Disease
Samuel M. Goldman
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 54 (2014)
Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells
Alisdair McNeill et al.
BRAIN (2014)
Mavoglurant as a treatment for Parkinson's disease
Dmitry Petrov et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2014)
Subpicomolar Diphenyleneiodonium Inhibits Microglial NADPH Oxidase with High Specificity and Shows Great Potential as a Therapeutic Agent for Neurodegenerative Diseases
Qingshan Wang et al.
GLIA (2014)
Double-Blind Study of the Actively Transported Levodopa Prodrug XP21279 in Parkinson's Disease
Peter A. LeWitt et al.
MOVEMENT DISORDERS (2014)
Gut Feelings About Smoking and Coffee in Parkinson's Disease
Pascal Derkinderen et al.
MOVEMENT DISORDERS (2014)
The mGluR5 Negative Allosteric Modulator Dipraglurant Reduces Dyskinesia in the MPTP Macaque Model
Erwan Bezard et al.
MOVEMENT DISORDERS (2014)
Adenosine A2A receptor antagonism reverses inflammation-induced impairment of microglial process extension in a model of Parkinson's disease
Stefka Gyoneva et al.
NEUROBIOLOGY OF DISEASE (2014)
α-Synuclein Immunotherapy Blocks Uptake and Templated Propagation of Misfolded α-Synuclein and Neurodegeneration
Hien T. Tran et al.
CELL REPORTS (2014)
Low Dose Bexarotene Treatment Rescues Dopamine Neurons and Restores Behavioral Function in Models of Parkinson's Disease
Krista McFarland et al.
ACS CHEMICAL NEUROSCIENCE (2013)
Parkinson's disease, insulin resistance and novel agents of neuroprotection
Iciar Aviles-Olmos et al.
BRAIN (2013)
Simvastatin Induces Neuroprotection in 6-OHDA-Lesioned PC12 via the PI3K/AKT/Caspase 3 Pathway and Anti-Inflammatory Responses
Yun-Qi Xu et al.
CNS NEUROSCIENCE & THERAPEUTICS (2013)
Glutathione metabolism and Parkinson's disease
Michelle Smeyne et al.
FREE RADICAL BIOLOGY AND MEDICINE (2013)
Exenatide and the treatment of patients with Parkinson's disease
Iciar Aviles-Olmos et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial
Robert A. Hauser et al.
LANCET NEUROLOGY (2013)
The Lewy Body in Parkinson's Disease and Related Neurodegenerative Disorders
Koichi Wakabayashi et al.
MOLECULAR NEUROBIOLOGY (2013)
Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease
Yoshikuni Mizuno et al.
MOVEMENT DISORDERS (2013)
NURR1 in Parkinson disease-from pathogenesis to therapeutic potential
Mickael Decressac et al.
NATURE REVIEWS NEUROLOGY (2013)
The many faces of alpha-synuclein: from structure and toxicity to therapeutic target
Hilal A. Lashuel et al.
NATURE REVIEWS NEUROSCIENCE (2013)
Meta-Analysis of Early Nonmotor Features and Risk Factors for Parkinson Disease
Alastair J. Noyce et al.
ANNALS OF NEUROLOGY (2012)
Cholinergic Deficit and Response to Donepezil Therapy in Parkinson's Disease with Dementia
Kotaro Hiraoka et al.
EUROPEAN NEUROLOGY (2012)
The link between the GBA gene and parkinsonism
Ellen Sidransky et al.
LANCET NEUROLOGY (2012)
Donepezil in Parkinson's disease dementia: A randomized, double-blind efficacy and safety study
Bruno Dubois et al.
MOVEMENT DISORDERS (2012)
Gaucher Disease Glucocerebrosidase and α-Synuclein Form a Bidirectional Pathogenic Loop in Synucleinopathies
Joseph R. Mazzulli et al.
CELL (2011)
Mitochondrial complex I impairment in leukocytes from type 2 diabetic patients
Antonio Hernandez-Mijares et al.
FREE RADICAL BIOLOGY AND MEDICINE (2011)
Simvastatin Prevents Dopaminergic Neurodegeneration in Experimental Parkinsonian Models: The Association with Anti-Inflammatory Responses
Junqiang Yan et al.
PLOS ONE (2011)
α6β2*and α4β2*Nicotinic Acetylcholine Receptors As Drug Targets for Parkinson's Disease
Maryka Quik et al.
PHARMACOLOGICAL REVIEWS (2011)
In vivo demonstration that α-synuclein oligomers are toxic
Beate Winner et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Monoamine Oxidase Inhibitors as Neuroprotective Agents in Age-Dependent Neurodegenerative Disorders
Makoto Naoi et al.
CURRENT PHARMACEUTICAL DESIGN (2010)
PGC-1α, A Potential Therapeutic Target for Early Intervention in Parkinson's Disease
Bin Zheng et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
A Nurr1/CoREST Pathway in Microglia and Astrocytes Protects Dopaminergic Neurons from Inflammation-Induced Death
Kaoru Saijo et al.
CELL (2009)
Antagonists of the Human A2A Adenosine Receptor. 4. Design, Synthesis, and Preclinical Evaluation of 7-Aryltriazolo[4,5-d]pyrimidines
Roger J. Gillespie et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Nicotine is neuroprotective when administered before but not after nigrostriatal damage in rats and monkeys
Luping Z. Huang et al.
JOURNAL OF NEUROCHEMISTRY (2009)
GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism
Yazhou Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Adenosine A2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms
Liqun Yu et al.
ANNALS OF NEUROLOGY (2008)
Statins reduce neuronal α-synuclein aggregation in in vitro models of Parkinson's disease
Pazit Bar-On et al.
JOURNAL OF NEUROCHEMISTRY (2008)
Temporal relationship between cigarette smoking and risk of Parkinson disease
E. L. Thacker et al.
NEUROLOGY (2007)
How to make a mesodiencephalic dopaminergic neuron
Marten P. Smidt et al.
NATURE REVIEWS NEUROSCIENCE (2007)
The aggregation and fibrillation of α-synuclein
Anthony L. Fink
ACCOUNTS OF CHEMICAL RESEARCH (2006)
Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease
Susan H. Fox et al.
ARCHIVES OF NEUROLOGY (2006)
Perspectives on MAO-B in aging and neurological disease - Where do we go from here?
MJ Kumar et al.
MOLECULAR NEUROBIOLOGY (2004)
NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease
DC Wu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
A novel neutrotrophic property of glucagon-like peptide 1: A promoter of nerve growth factor-mediated differentiation in PC12 cells
T Perry et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Share Paper
